Expanding Cancer Treatment Options Where None Exist Today

1 in 10 solid cancer patients are untreatable or inoperable

In 2020, there were 19.3 million new cancer cases worldwide and 10 million deaths. This global burden is predicted to reach 29.4 million cases by 2040. 

90% of these cases are solid tumors affecting about 17.4 million patients. Yet, 1 in 10 of these patients have no treatment option. At Intragel we aim to change this.

90% of patients
have a solid tumor
1-of-10

First Application for Head and Neck Cancer

Intragel is developing safe, efficacious and lifesaving treatments for solid cancer patients, that will answer the unmet need of inoperable or untreatable solid tumors, starting with head and neck cancer (HNC).

Affecting more than 900,000 people globally, HNC is a very stubborn cancer and often diagnosed at a late stage resulting in a generally poor prognosis. As a result, 50-60% of patients develop recurrence and become unfit for chemotherapy or surgery, leaving patients with palliative treatments and no hope of recovery.

As a treatment for this high unmet medical need showing positive results, Intragel anticipates pursuing an expedited 505(b)(2) regulatory approval process.

Clinical Progress in Head and Neck Cancer

Intragel is currently conducting a Compassionate Use Program with Medias Klinikum in Germany as well as a Phase 1b clinical trial with Sharet Institute, Hadassah Ein Kerem Medical Center (Jerusalem), Assuta Ashdod Hospital (Ashdod), Carmel Medical Center (Haifa), Ichilov-Tel Aviv Sourasky Medical Center or Galilee Medical Center (Nahariya) in Israel. 

This single-arm, open-label, prospective, multicenter Phase 1B study aims to evaluate the safety and efficacy of TumoCure in patients with progressive or radio-resistant primary head and neck tumors. Initial results from both programs have promising safety and efficacy. 

Compassionate Use Program

three patients have been treated with both chemo-resistant HNC carcinoma and lower body sarcomas. In all cases more 35% tumor shrinkage was observed after 1 month, while the third patient showed full response and complete elimination of tumor which saved his body part from amputation.

Phase 1B Clinical Study

The clinical trial is ongoing. Initial results from first three patients indicate that the treatment is both safe and well-tolerated, accompanied by noticeable tumor reduction.

Intragel Clinical Pipeline

In addition to addressing this medical gap, SRGel technology is being adapted to meet other critical unmet medical needs. Early-stage applications are underway for lung cancer and brain glioblastoma, with prospective solutions for colorectal, ovarian, and testicular cancers under consideration.

Current Pipeline